For example, combination treatments involving TGF-β inhibitors and anti-PD-L1 immunotherapy can reduce TGF-β signaling in stromal cells, leading to increased T cell infiltration, and improved anti-tumor immunity [177]. The gene discussed is TGFB1; the disease is neoplasm.